Evidence map›Paper›PMID 22170067›Full record

Trial reportThe Journal of biological chemistry2012

Mechanisms of rapid induction of interleukin-22 in activated T cells and its modulation by cyclosporin a.

Ina Rudloff, Malte Bachmann, Josef Pfeilschifter, Heiko Mühl

Open access · hybridAbstract readClinical Trial
In one paragraph

Trial report in The Journal of biological chemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Ina RudloffPharmazentrum Frankfurt/Zentrum für Arzneimittelforschung, Entwicklung und Sicherheit, University Hospital Goethe-University Frankfurt, Frankfurt am Main 60590, Germany.
Malte Bachmann
Josef Pfeilschifter
Heiko Mühl
Goethe University Frankfurt · DE

Funding

Data-Based Methods for Just-In-Time Adaptive Interventions in Alcohol UseR01AA023187 · NIAAA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MURPHY, SUSAN A · 2015 to 2019
$2.6M
NIAAA NIH HHS R01 AA023187
6 · The paper itself

Abstract

IL-22 is an immunoregulatory cytokine displaying pathological functions in models of autoimmunity like experimental psoriasis. Understanding molecular mechanisms driving IL-22, together with knowledge on the capacity of current immunosuppressive drugs to target this process, may open an avenue to novel therapeutic options. Here, we sought to characterize regulation of human IL22 gene expression with focus on the established model of Jurkat T cells. Moreover, effects of the prototypic immunosuppressant cyclosporin A (CsA) were investigated. We report that IL-22 induction by TPA/A23187 (T/A) or αCD3 is inhibited by CsA or related FK506. Similar data were obtained with peripheral blood mononuclear cells or purified CD3(+) T cells. IL22 promoter analysis (-1074 to +156 bp) revealed a role of an NF-AT (-95/-91 nt) and a CREB (-194/-190 nt) binding site for gene induction. Indeed, binding of CREB and NF-ATc2, but not c-Rel, under the influence of T/A to those elements could be proven by ChIP. Because CsA has the capability to impair IκB kinase (IKK) complex activation, the IKKα/β inhibitor IKKVII was evaluated. IKKVII likewise reduced IL-22 induction in Jurkat cells and peripheral blood mononuclear cells. Interestingly, transfection of Jurkat cells with siRNA directed against IKKα impaired IL22 gene expression. Data presented suggest that NF-AT, CREB, and IKKα contribute to rapid IL22 gene induction. In particular the crucial role of NF-AT detected herein may form the basis of direct action of CsA on IL-22 expression by T cells, which may contribute to therapeutic efficacy of the drug in autoimmunity.

Indexed as

Autoimmune DiseasesCalcimycinCalcium IonophoresCarcinogensCyclosporineFemaleGene Expression RegulationHumansI-kappa B KinaseImmunosuppressive AgentsInterleukin-22InterleukinsJurkat CellsLymphocyte ActivationMaleResponse ElementsCalcimycinCalcium IonophoresCarcinogensCyclosporineI-kappa B KinaseImmunosuppressive AgentsInterleukin-22InterleukinsTetradecanoylphorbol AcetateTranscription Factors

Identifiers

PMID22170067
PMCPMC3281663
OpenAlexW2069042187

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.